Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > Partnership > EORTC > EORTC calls for the interests of patients to take centre stage in the development of new treatments

EORTC calls for the interests of patients to take centre stage in the development of new treatments

  • 21 February 2020
  • External Contributor
Total
0
Shares
0
0
0
0
0

With the arrival of precision medicine, the days of the old ‘one size fits all’ treatments seem long in the past. Precision oncology and new approaches to clinical research have meant a dramatic change in the field of cancer treatment. But precision medicine, promising as it is, brings its own challenge – how can we be sure that these targeted treatments are used optimally to the benefit of the individual patient?

New treatments now become available based on solid scientific rationale, thanks to our understanding of molecular biology and immunology. However, optimal use of new anti-cancer treatments remains poorly documented. Optimal patient population and cut-off values of biomarkers, treatment duration, sequence and combination are rarely informed, leaving patients, doctors and society facing many questions. In addition, all this is exacerbated by the often very high cost of new treatments. It is therefore essential to find an equilibrium between the interests and needs of all stakeholders, and define it around patientcentredness.

A newer version of the Clinical Trial Regulation will soon be implemented in Europe. However, it is not yet known whether it will address the issue of the qualification of studies designed to answer questions centred on patient care. On the contrary, it raises the risks that all Member States could adopt a position not necessarily based on medically informed criteria, and risks making therapeutic strategy trials yet more challenging to perform in the EU.

The current drug development paradigm has been criticised for being too drug-centred, and not focusing sufficiently on the patients who will eventually be consumers of the new therapies. A recent EORTC manifesto aims to try to find the balance between the interests and requirements of stakeholders (bit.ly/EORTC_ Treatment-Optimisation-Manifesto).

The EORTC consulted academic clinicians, representatives of patient organisations, regulatory and payer authorities, health technology assessments agencies, and industry. We now have much greater clarity on what is needed to put patients at the centre of the drug development process, and we were pleased to find that all stakeholders considered treatment optimisation tools to be valuable to address current gaps in evidence.

Treatment optimisation is a process intended to enhance the long term efficacy, adherence, safety, convenience and affordability of a therapy. Its ultimate goal is to expand access to effective treatment to all of those it will benefit. Currently, European patients and the healthcare system are penalised rather than aided by the regulatory hurdle. We need greater independence in assessing the role of treatments. Urgent reform is needed to assess interventional clinical research based on purpose and treatment modalities, not necessarily through the rigid application of inappropriate frameworks.

For more information visit: www.eortc.org

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
External Contributor

You May Also Like
View Post
  • Obituaries

Hansjörg Senn of St Gallen: A practice-changing career

  • Anna Wagstaff
  • 3 February 2023
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • Articles
  • Policy

The cancer patients still struggling to access drugs in the wake of anti-corruption reforms

  • Giselle Vidal
  • 27 January 2023
View Post
  • Supported contents

AI in Genomics and Reporting for Clinical Practice

  • Adriana Albini
  • 26 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • Articles
  • Delivery of Care

Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access

  • Swagata Yadavar
  • 26 January 2023
View Post
  • Supported contents

Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care

  • Adriana Albini
  • 23 January 2023
View Post
  • Articles
  • Policy

Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions

  • Esther Nakkazi
  • 12 January 2023
search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • Hansjörg Senn of St Gallen: A practice-changing career
    • 3 February 2023
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.